This is a proposal to renew the ongoing, productive drug abuse Treatment Research Center located in the John Hopkins Behavioral Pharmacology Research Unit. The Center unites a group of innovative and productive drug abuse clinical researchers with complementary interests and approaches who share a commitment to the scientific study of drug abuse as a behavioral pharmacologic disorder. The Center integrates human laboratory research with outpatient clinical trials research. Its clinical research resources training and career development resources, and scientific reputation and productivity are outstanding. The general theme for this renewal period is that of treatment comparisons. Five specific components plus a Core are proposed. A human laboratory component will use a naloxone-precipitated withdrawal model to evaluate medications that may suppress the opioid withdrawal syndrome. A second human laboratory component will evaluate factors that influence the persistence of heroin-self administration during methadone maintenance treatment. A clinical trial component will assess the individual and combined effects of opioid pharmacotherapy dose and varied incentive-based behavior therapy """"""""doses"""""""" in treating combined opioid and cocaine abuse; this study will help to identify which intensities of psychosocial treatment most sensitively reveal the efficacy of pharmacotherapies. A second clinical trial component will assess whether a specific behavior therapy previously shown to be an effective adjunct to methadone--behaviorally-contingent pharmacotherapy--is also effective as an adjunct to LAAM. The fifth component involves both human laboratory studies and clinical trials: human laboratory studies will compare the withdrawal syndromes following discontinuation of methadone, LAAM and buprenorphine; a clinical trial will compare the efficacies and patient acceptabilities of methadone, LAAM and buprenorphine in detoxification treatment. A Core component provides shared resources for patient recruitment, urinalysis testing, statistical analyses, technical/computer support, psychiatric/behavioral assessment, medical supervision, pharmacy preparations, and office and administrative support.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA005273-13
Application #
6175024
Study Section
Special Emphasis Panel (ZDA1-MXC-A (05))
Program Officer
Oversby, Steven
Project Start
1988-09-30
Project End
2003-06-30
Budget Start
2000-07-01
Budget End
2001-06-30
Support Year
13
Fiscal Year
2000
Total Cost
$1,983,351
Indirect Cost
Name
Johns Hopkins University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Peirce, Jessica M; Kindbom, Kori A; Waesche, Matthew C et al. (2008) Posttraumatic stress disorder, gender, and problem profiles in substance dependent patients. Subst Use Misuse 43:596-611
Burke, Christopher K; Peirce, Jessica M; Kidorf, Michael S et al. (2008) Sleep problems reported by patients entering opioid agonist treatment. J Subst Abuse Treat 35:328-33
Wedam, Erich F; Bigelow, George E; Johnson, Rolley E et al. (2007) QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 167:2469-75
Sigmon, Stacey C (2007) Investigating the pharmacological and nonpharmacological factors that modulate drug reinforcement. Exp Clin Psychopharmacol 15:1-20
Carroll, C Patrick; Kidorf, Michael; Strain, Eric C et al. (2007) Comparison of demographic and clinical characteristics between opioid-dependent individuals admitted to a community-based treatment setting and those enrolled in a research-based treatment setting. J Subst Abuse Treat 33:355-61
Lott, David C; Strain, Eric C; Brooner, Robert K et al. (2006) HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone. J Subst Abuse Treat 31:187-94
Sigmon, Stacey C; Moody, David E; Nuwayser, Elie S et al. (2006) An injection depot formulation of buprenorphine: extended bio-delivery and effects. Addiction 101:420-32
Jones, Hendree E; Fitzgerald, Heather; Johnson, Rolley E (2005) Males and females differ in response to opioid agonist medications. Am J Addict 14:223-33
Lofwall, Michelle R; Brooner, Robert K; Bigelow, George E et al. (2005) Characteristics of older opioid maintenance patients. J Subst Abuse Treat 28:265-72
Disney, Elizabeth R; Kidorf, Michael; King, Van L et al. (2005) Prevalence and correlates of cocaine physical dependence subtypes using the DSM-IV in outpatients receiving opioid agonist medication. Drug Alcohol Depend 79:23-32

Showing the most recent 10 out of 44 publications